EVOK
🚫 does not pay dividends

Company News

Halper Sadeh LLC Encourages EVOK, FSFG, BRY Shareholders to Contact the Firm to Discuss Their Rights
GlobeNewswire Inc. • Halper Sadeh Llc • December 2, 2025

Law firm investigating potential securities law violations and fiduciary duty breaches for three companies undergoing mergers or acquisitions.

$HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger—TRUE, BRY, EVOK, and FSFG
GlobeNewswire Inc. • Juan Monteverde • December 1, 2025

Law firm Monteverde & Associates is investigating merger transactions for multiple companies, alerting shareholders about potential legal actions related to recent corporate sales and mergers.

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger-HBAN, AVDL, EVOK, and TRUE
Benzinga • Juan Monteverde • November 13, 2025

Law firm Monteverde & Associates is investigating potential legal actions related to merger transactions involving Huntington Bancshares, Avadel Pharmaceuticals, Evoke Pharma, and trueCar.

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kenvue Inc. (NYSE - KVUE), Sonida Senior Living, Inc. (NYSE - SNDA), Evoke Pharma Inc. (Nasdaq - EVOK), SM Energy Company (NYSE - SM)
GlobeNewswire Inc. • Brodsky & Smith • November 5, 2025

Law firm Brodsky & Smith is investigating potential breaches of fiduciary duties by boards of several companies during merger and acquisition processes, focusing on whether shareholders are receiving fair value.

Evoke Pharma Rockets On Grabbing 140% Premium In Acquisition Deal
Benzinga • Lekha Gupta • November 4, 2025

Evoke Pharma will be acquired by QOL Medical for $11 per share in cash, representing a 139.7% premium over its previous closing price. The deal is expected to close by the end of 2025 and highlights the strategic value of GIMOTI, Evoke's FDA-approved nasal spray for diabetic gastroparesis.

Related Companies